Healio
SearchLoading
Healio
SearchLoading
SABCS targeted therapies take home banner

Take Homes from SABCS: Targeted Therapies
ByNancy U. Lin, MD

Read more

December 16, 2020
1 min watch
Save

VIDEO: Despite negative results, IPATunity130 trial reveals more on targeting pathways in breast cancer

ByNancy U. Lin, MD

Despite the phase 3 study IPATunity130 demonstrating negative results, the presentation of the data at San Antonio Breast Cancer Symposium 2020 will still be “interesting,” according to Nancy U. Lin, MD.

“There is much interest in targeting other parts of the PI3K/AKT pathway,” Lin, an associate professor at Harvard Medical School and clinical director of the Breast Oncology Center at Dana-Farber Cancer Institute.

Sources/Disclosures

Collapse
Source:

Dent R, et al. Abstract GS3-04. Presented at: San Antonio Breast Cancer Symposium (Virtual); Dec. 8-11, 2020.

Disclosures: Lin reports serving as a consultant with AstraZeneca and receiving grant support from Genentech and Seattle Genetics.

Read more from Take Homes from SABCS: Targeted Therapies

View all

Read more about

breast cancer
paclitaxel
metastatic triple-negative breast cancer
 

Related Content